首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL3 |
| Uniprot No | P10147 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-92aa |
| 氨基酸序列 | SLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA |
| 预测分子量 | 14.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Expression and characterization of recombinant human MIP-1α (CCL3) in Escherichia coli"**
- Author: J. Smith et al.
- 摘要：该研究描述了一种通过大肠杆菌系统高效表达和纯化重组人CCL3(MIP-1α)的方法，并验证其体外趋化活性及与CCR1受体的结合能力。
2. **"Functional analysis of CCL3 in dendritic cell migration using a recombinant murine model"**
- Author: L. Chen & R. Patel
- 摘要：通过重组小鼠CCL3蛋白研究其在树突状细胞迁移中的作用，发现其通过激活CCR5信号通路促进免疫细胞招募，为炎症治疗提供依据。
3. **"Structural and functional insights into CCL3 glycosylation variants"**
- Author: M. Tanaka et al.
- 摘要：比较不同糖基化修饰的重组CCL3蛋白，揭示糖链结构对其稳定性和趋化功能的影响，强调重组蛋白表达系统选择的重要性。
4. **"Recombinant CCL3 enhances antitumor immunity by modulating macrophage polarization"**
- Author: K. Johnson et al.
- 摘要：研究发现重组CCL3通过诱导肿瘤相关巨噬细胞向M1表型极化，抑制小鼠肿瘤生长，突显其在癌症免疫治疗中的潜力。
(注：以上为示例性文献，实际引用需查询具体数据库如PubMed或Google Scholar获取真实研究。)
**Background of Recombinant CCL3 Protein**
CCL3 (C-C motif chemokine ligand 3), also known as macrophage inflammatory protein-1 alpha (MIP-1α), is a small cytokine belonging to the CC chemokine family. It is encoded by the *CCL3* gene in humans and plays a critical role in immune responses by recruiting and activating leukocytes, particularly monocytes, macrophages, neutrophils, and dendritic cells, to sites of inflammation or infection. CCL3 exerts its biological effects by binding to chemokine receptors CCR1. CCR4. and CCR5. which are G protein-coupled receptors expressed on target cells. This interaction triggers intracellular signaling pathways that regulate cell migration, adhesion, and activation.
Recombinant CCL3 protein is a genetically engineered version of the native chemokine, produced using expression systems such as *E. coli* or mammalian cells. The recombinant form is designed to mimic the natural protein’s structure and function, ensuring high purity and bioactivity for research and therapeutic applications. Its production typically involves cloning the *CCL3* gene into an expression vector, followed by protein purification using techniques like affinity chromatography.
In research, recombinant CCL3 is widely used to study inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis), infectious diseases, and cancer. It serves as a tool to investigate chemokine-mediated immune cell trafficking, immune regulation, and pathological mechanisms. Additionally, CCL3 has been implicated in HIV pathogenesis due to its interaction with CCR5. a co-receptor for viral entry, making it a potential target for antiviral therapies.
The development of recombinant CCL3 has advanced drug discovery, enabling the screening of inhibitors or modulators for therapeutic interventions. Its applications extend to *in vitro* cell migration assays, animal disease models, and biomarker studies, underscoring its importance in immunology and biomedical research.
×
